5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.98▲ | 1.97▲ | 1.97▲ | 1.86▲ | 1.79▲ |
MA10 | 1.98▲ | 1.98▲ | 1.95▲ | 1.81▲ | 1.52▲ |
MA20 | 1.97▲ | 1.91▲ | 1.88▲ | 1.72▲ | 1.37▲ |
MA50 | 1.89▲ | 1.83▲ | 1.79▲ | 1.38▲ | 1.37▲ |
MA100 | 1.80▲ | 1.71▲ | 1.66▲ | 1.33▲ | 1.87▲ |
MA200 | 1.67▲ | 1.44▲ | 1.37▲ | 1.36▲ | 4.39▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.003▼ | 0.001▲ | 0.009▲ | 0.009▲ | 0.101▲ |
RSI | 57.660▲ | 59.192▲ | 61.349▲ | 65.810▲ | 66.530▲ |
STOCH | 67.593 | 74.644 | 88.629▲ | 65.411 | 87.719▲ |
WILL %R | -11.111▲ | -7.692▲ | -3.571▲ | -12.283▲ | -5.366▲ |
CCI | 38.289 | 70.301 | 74.168 | 148.123▲ | 128.109▲ |
Tuesday, May 13, 2025 05:00 AM
Backed by Apyx Medical’s expertise and evidence-based ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the ...
|
Tuesday, May 13, 2025 05:00 AM
--Apyx Medical Corporation, the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ®, is pleased to announce it has received 510 clearance ...
|
Tuesday, May 13, 2025 03:40 AM
Apyx Medical (NASDAQ: APYX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.10 per share a year ago.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
23/06/25 | 1.965 | 2.00 | 1.91 | 1.99 | 77,445 |
20/06/25 | 1.87 | 2.00 | 1.77 | 2.00 | 79,754 |
18/06/25 | 1.79 | 2.06 | 1.7005 | 1.71 | 156,934 |
17/06/25 | 1.85 | 1.9154 | 1.76 | 1.76 | 27,685 |
16/06/25 | 1.83 | 2.00 | 1.7623 | 1.86 | 61,696 |
13/06/25 | 1.72 | 1.85 | 1.644 | 1.75 | 33,156 |
12/06/25 | 1.73 | 1.77 | 1.6857 | 1.715 | 17,441 |
11/06/25 | 1.81 | 1.85 | 1.75 | 1.76 | 24,655 |
10/06/25 | 1.76 | 1.84 | 1.72 | 1.84 | 86,280 |
09/06/25 | 1.73 | 1.7999 | 1.59 | 1.73 | 68,436 |
|
|
||||
|
|
||||
|
|